Compare BBIO & CF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBIO | CF |
|---|---|---|
| Founded | 2015 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.5B |
| IPO Year | 2019 | 2005 |
| Metric | BBIO | CF |
|---|---|---|
| Price | $78.86 | $91.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 14 |
| Target Price | $78.81 | ★ $88.54 |
| AVG Volume (30 Days) | ★ 2.9M | 2.5M |
| Earning Date | 02-19-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 31.44 |
| EPS | N/A | ★ 8.27 |
| Revenue | $353,780,000.00 | ★ $6,736,000,000.00 |
| Revenue This Year | $129.14 | $21.06 |
| Revenue Next Year | $78.96 | N/A |
| P/E Ratio | ★ N/A | $10.86 |
| Revenue Growth | ★ 62.46 | 12.59 |
| 52 Week Low | $28.33 | $67.34 |
| 52 Week High | $81.33 | $104.45 |
| Indicator | BBIO | CF |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 61.75 |
| Support Level | $76.25 | $88.78 |
| Resistance Level | $80.00 | $95.21 |
| Average True Range (ATR) | 2.73 | 2.92 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 68.43 | 72.07 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.